Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2017 | New trials in relapsed high-grade lymphomas

Graham Collins • 27 Mar 2017
BSH 2017
Diffuse Large B-Cell Lymphoma Hodgkin Lymphoma Checkpoint inhibitors Nivolumab Vistusertib
TORCH

Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, from the Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses new clinical trials in relapsed high-grade lymphomas at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. He speaks about a planned trial of the PD-1 inhibitor nivolumab as a bridge to stem cell transplantation in relapsed Hodgkin Lymphoma. In high-grade lymphoma, Dr Collins is running the TORCH trial (NCT02752204) of the next-generation mTOR inhibitor vistuserib in relapsed diffuse large B-cell lymphoma. He also highlights the potential of rational combination therapies in relapsed high-grade lymphomas.

More from Graham Collins

Future frontline Hodgkin lymphoma strategies aim to reduce treatment toxicity
1:43
Future frontline Hodgkin lymphoma strategies aim to reduce treatment toxicity
Graham Collins • 13 Jun 2026
AVENUE final analysis supports frontline avelumab in Hodgkin lymphoma
1:27
AVENUE final analysis supports frontline avelumab in Hodgkin lymphoma
Graham Collins • 13 Jun 2026
BrECADD vs Nivo-AVD in advanced Hodgkin lymphoma: selecting the right patients
2:09
BrECADD vs Nivo-AVD in advanced Hodgkin lymphoma: selecting the right patients
Graham Collins • 13 Jun 2026
Current treatment approaches for relapsed Hodgkin lymphoma & challenges that remain
3:22
Current treatment approaches for relapsed Hodgkin lymphoma & challenges that remain
Graham Collins • 28 May 2025

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Community lymphoma management: which patients should be prioritized for specialist referral?
1:16
Community lymphoma management: which patients should be prioritized for specialist referral?
Nirav Niranjan Shah • 10 Sep 2026
Community-based management of CAR-T and bispecific antibody-related CRS in B-cell lymphoma
2:17
Community-based management of CAR-T and bispecific antibody-related CRS in B-cell lymphoma
Michael Jain • 11 Sep 2026
Optimizing post-CAR-T monitoring and community delivery after liso-cel
1:04
Optimizing post-CAR-T monitoring and community delivery after liso-cel
Bradley Hunter • 21 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals